Risk factor
Strong & resilient to price shocks
Profitability factor
Low dividends
About
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV
Target Price
The average target price of PPLPHARMA.NS is 193 and suggests 15% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation